神經生物標記市場報告：2030 年趨勢、預測與競爭分析

神經生物標記的趨勢和預測

預計到 2030 年，全球神經生物標記市場將達到約 147 億美元，2024 年至 2030 年的複合年成長率為 11.7%。該市場的主要驅動力是液態切片的日益普及、人工智慧 (AI) 在神經生物標記開發中的使用增加以及個人化醫療需求的不斷成長。全球神經生物標記市場的未來充滿希望，醫院/醫院實驗室、獨立臨床診斷中心和研究機構市場都有機會。

• Lucintel 預測，由於神經系統疾病的盛行率不斷增加，蛋白質體學將在預測期內按類型經歷最高的成長。
• 由於醫院和醫院實驗室被認為是神經系統疾病診斷服務的主要提供者，因此最終用途類別預計將出現最高成長。
• 按地區分類，由於阿茲海默症、帕金森氏症和多發性硬化症等神經系統疾病的高盛行率以及該地區醫療保健支出的增加，北美在預測期內仍將是最大的地區。

神經生物標記市場的策略性成長機會

神經生物標記的策略性成長機會出現在多個應用領域。這些範圍從技術進步到專注於改進診斷和治療方法的技術進步，為神經系統疾病管理之外的進一步市場擴張提供了潛力。

• 阿茲海默症：阿茲海默症的盛行率不斷上升，為神經生物標記的擴展開闢了主要途徑。目前正在進行生物標記研究，以確定用於早期檢測和監測疾病進展的新標記。診斷和追蹤老年失智症的生物標記將改變治療結果，並且對於控制疾病至關重要。
• 帕金森氏症神經生物標記市場的其他關鍵成長領域包括帕金森氏症。帕金森氏症的生物標記研究正在興起，新的標記被發現可以監測疾病進展和治療反應。帕金森氏症患者迫切需要更好的診斷工具和個人化治療方案，推動了這一領域的機會。
• 多發性硬化症：多發性硬化症的生物標記是一個越來越受關注的領域。神經影像學和生物標記研究的進步正在增加多發性硬化症早期診斷和追蹤的前景。開發充分反映疾病活動和進展的生物標記對於最佳化治療策略和改善患者預後尤為重要。
• 中風和創傷性腦損傷：中風和創傷性腦損傷的生物標記越來越受到研究的關注，重點是早期檢測和管理。能夠快速識別和評估腦損傷的生物標記代表著巨大的發展和成長機會。這些生物標記能夠進行早期療育並幫助患者從中風和創傷性腦損傷的影響中恢復。
• 發炎和神經退化性疾病：發炎和神經退化性疾病的生物標記數量持續成長。與發炎過程相關的生物標記可以更好地理解和管理多發性硬化症和阿茲海默症病理狀況。非常需要改進發炎和神經退化的診斷和治療工具。

這種策略性成長機會透過培育創新的診斷和治療方法來推動神經生物標記市場。以阿茲海默症、帕金森氏症、多發性硬化症、中風和發炎為重點，開發與個人化治療方案相關的更好的生物標記物，以改善神經系統疾病的治療進展正在加速。

神經生物標記市場的促進因素與挑戰

有一些影響神經生物標記市場的主要促進因素/挑戰。技術進步、經濟因素和監管因素可以顯著影響市場動態。 雖然促進因素支持成長和創新，但必須克服成本、監管和技術整合挑戰，才能充分發揮神經生物標記的潛力。

推動神經生物標記市場的因素包括：

• 技術進步：神經生物標記市場的成長主要受到人工智慧和神經影像等技術進步的影響。這些技術有助於提高生物標記分析的準確性和速度，從而實現神經系統疾病的準確診斷和有效管理。科技的持續創新提高了生物標記研究的力量和有效性，並改善了患者的治療結果。
• 神經系統疾病的盛行率不斷上升：推動市場成長的主要因素是阿茲海默症、帕金森氏症和多發性硬化症等神經系統疾病的盛行率不斷上升。隨著這些負擔的增加，對先進診斷工具和生物標記以改善早期診斷和治療的需求將會增加。這一趨勢正在推動該領域的研究和發展。
• 增加研發投入：神經生物標記市場的開拓將由研發投入的增加所推動。政府機構、研究機構和私人組織正在資助新生物標記和診斷工具的開發，以實現快速創新並為神經病學的進步做出貢獻。
• 關注個人化醫療：個人化醫療的趨勢正在推動生物標記的發展，從而為個別患者提供針對性的治療。基因組學和蛋白​​質組學的進步使得能夠識別特定患者基因譜特有的生物標記。這些趨勢繼續帶來更有效的治療、更好的結果和增強的患者照護。
• 早期診斷的需求不斷成長：為了應對神經系統疾病早期診斷日益成長的需求，新的生物標記正在開發中。這種關注有助於確保有效的治療和管理，因為阿茲海默症和帕金森氏症等疾病需要及時發現。對早期診斷的日益重視加速了對能夠在疾病早期識別的生物標記的研究。

神經生物標記市場的挑戰包括：

• 高開發和實施成本：該市場的主要挑戰之一是先進生物標記的高開發和實施成本。與研發、監管核准和臨床試驗相關的高度可變的成本限制了新型生物標記的獲取並影響了市場。
• 監管和報銷問題：滿足新型生物標記的監管要求和報銷是很困難的。冗長的監管程序和多樣化的報銷政策可能會減緩新診斷工具的推出並降低其可用性。解決這些問題對於成功商業化至關重要。
• 與現有系統整合：新的生物標記和診斷在與現有醫療保健系統整合時通常面臨挑戰。與現有系統的兼容性和互通性是成功實施的關鍵。先進的生物標記可以顯著改善診斷工作流程，如果要充分獲得好處，就必須解決這些整合問題。

目錄

第1章執行摘要

第2章全球神經生物標記市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球神經生物標記市場趨勢（2018-2023）與預測（2024-2030）
• 按類型：全球神經生物標記市場
  • 基因組
  • 蛋白質體
  • 代謝體學
  • 影像
  • 其他
• 按應用：全球神經生物標記市場
  • 阿茲海默症
  • 帕金森氏症
  • 多發性硬化症
  • 泛自閉症障礙
  • 其他
• 按最終用途分類的全球神經生物標記市場
  • 醫院和醫院實驗室
  • 獨立臨床診斷中心
  • 研究機構等

第4章 2018-2030年區域市場趨勢及預測分析

• 按地區分類的全球神經生物標記市場
• 北美神經生物標記市場
• 歐洲神經生物標記市場
• 亞太神經生物標記市場
• 其他地區的神經生物標記市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 按類型：全球神經生物標記市場成長機會
  • 按應用：全球神經生物標記市場的成長機會
  • 全球神經生物標記市場的成長機會（按最終用途分類）：
  • 按地區：全球神經生物標記市場成長機會
• 全球神經生物標記市場的新興趨勢
• 戰略分析
  • 新產品開發
  • 全球神經生物標記市場的產能擴張
  • 全球神經生物標記市場的合併、收購和合資企業
  • 認證和許可

第7章主要企業概況

• Abbott
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Merck
• Johnson & Johnson Services
• BANYAN BIOMARKERS
• Myriad Genetics

Neurological Biomarker Trends and Forecast

The future of the global neurological biomarker market looks promising with opportunities in the hospital & hospital laboratory, independent clinical diagnostic center, and research organizations markets. The global neurological biomarker market is expected to reach an estimated $14.7 billion by 2030 with a CAGR of 11.7% from 2024 to 2030. The major drivers for this market are the growing adoption of liquid biopsy, increasing utilization of artificial intelligence (AI) in neurological biomarker development, and rising demand for personalized medicine.

• Lucintel forecasts that, within the type category, proteomic is expected to witness the highest growth over the forecast period due to the increasing prevalence of neurological diseases.
• Within the end-use category, hospitals and hospital laboratories will witness the highest growth as they are considered as a primary provider of diagnostic services for neurological disorders.
• In terms of regions, North America will remain the largest region over the forecast period due to the high prevalence of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, and rising healthcare expenditure in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Neurological Biomarker Market

The emerging trends within the neurological biomarker market exhibit advancements in technology, concepts of personalized medicine, and increasing research studies. Each of these may collectively usher in a paradigm shift in the formulation and application of biomarkers for neurological disorders, offering more diagnostic accuracy and treatment tailored to individual needs.

• Integration of AI and Machine Learning: The integration of AI and machine learning in the analysis of neurological biomarkers may improve diagnostic precision and efficiency. AI algorithms can deeply analyze complex neuroimaging data, including data from biomarker assays, and identify patterns that can easily be overlooked in traditional techniques. This leads to more accurate and timely diagnoses, along with superior monitoring of disease progression and treatment response.
• Neuroimaging Techniques: Recent advances in neuroimaging modalities, such as high-resolution MRI and PET, enhance the ability to visualize and quantify biomarkers associated with neurological diseases. These advances provide more detailed pictures of brain structure and function, allowing for earlier identification and more precise monitoring of conditions such as Alzheimer's and multiple sclerosis.
• Personalized Medicine: The trend toward personalized medicine drives biomarker development, which will tailor treatment to the individual patient. Advances in genomics and proteomics are identifying biomarkers specific to each genetic profile for targeted therapies that are more effective. This approach, matching the patient with their unique biomarker profile, optimizes interventions while reducing adverse effects.
• Expanding Biomarker-based Clinical Trials: The acceleration in biomarker-targeted clinical trials is further speeding up the identification and validation processes of new biomarkers for neurological disorders. These studies will research new biomarkers that facilitate early disease diagnosis, monitor the course of the illness, and predict responses to various treatments. Growing investments in biomarker-related research translate into the development of novel diagnostic tools and therapeutic strategies.
• Enhanced Collaboration and Data Sharing: There is an increasing tendency toward collaborative data sharing between research institutions, healthcare providers, and technology companies. This collaborative effort enables the pooling of data and resources, accelerates biomarker discovery, and extends the development of diagnostic and therapeutic tools. Thus, this trend nurtures innovation and enhances overall efficacy in neurological biomarker research.

These emerging trends are reshaping the neurological biomarker market by improving diagnosis, extending personalized treatment options, and encouraging innovation through advanced technology coupled with collaborative research. The use of AI, improved imaging, and the concept of personalized medicine have become some of the most influential forces for change in this area, offering better management of neurological disorders.

Recent Developments in the Neurological Biomarker Market

The field of neurological disorders is experiencing significant growth, especially due to recent advancements in technological applications that have facilitated the integration of neurological biomarkers into the existing framework of diagnosis and treatment. There are three types of neurological disorder markers: proteins, genes, and imaging, which, when combined, provide key information about brain health and the progress of specific diseases. Given the trend showing an increase in neurodegenerative diseases such as Alzheimer's and Parkinson's, pattern biomarker identification will be emphasized, aimed at facilitating the early detection of diseases and personalized treatment for patients. From these changes, we expect to make great strides toward unraveling the mysteries surrounding many diverse neurological diseases and optimizing clinical management using enhanced diagnostic and therapeutic approaches.

• Discovery of Novel Biomarkers: There has been target-specific protein and metabolite detection, particularly from blood and cerebrospinal fluid samples, that have spearheaded this development through recent studies that have pinpointed and subsequently supported the existence of promising biomarkers in Alzheimer's and Parkinson's diseases. With the identification of such biomarkers, there are many advantages, such as increased diagnostic accuracy, which enables earlier intervention and improvements in disease progression, enhancing the prospects of finding new effective therapies.
• Advances in Imaging Techniques: There has been tremendous improvement in the use of advanced MRI and PET scan imaging among patients suffering from neurological disorders to detect changes. Such imaging techniques have advanced the diagnosis of these conditions as they can reveal structural and functional abnormalities of the brain even before signs or symptoms are reported. By doing so, these imaging techniques assist in the early diagnosis of diseases, enabling prompt treatment and influencing the subsequent course of treatment.
• Genomic and Epigenetic Focus: The combination of genomic and epigenetic analyses has led to a greater understanding of these mechanisms in the context of neurological disorders. Researchers identify which genetic markers are related to diseases and how those genes cause them, subsequently examining preventive measures and intervention strategies. Personalizing treatment of this nature is a significant breakthrough, allowing strategies to be tailored to match the bioinformation of an individual.
• Relationship with Microbiome: An emerging body of evidence links the gut microbiome to the brain and, consequently, to brain disorders. Changes in gut bacteria have been associated with multiple sclerosis and autism spectrum disorders. If such connections are understood, it is feasible to devise new and more effective approaches for diseases through the use of new biomarkers, alongside modulating the microbiome of the host.
• Digital Biomarkers: The advent of wearable devices and mobile health apps has offered a solution to the limitations posed by traditional biobanks, in the form of digital biomarkers that detect and record behavioral and physiological actions. Such tools permit longitudinal measurement of brain-level activity and the occurrence of disease-related symptoms, providing objective data on the course of the disease and the impact of interventions, thus increasing patient engagement and individualization of care.

Overall, these advances in neurological biomarkers bring a paradigm shift in terms of diagnosis and therapeutic interventions in neurological disorders. Thanks to novel biomarker capabilities and technologies, as well as genomic, microbiome, and digital advances, these innovations will facilitate early recognition, optimize patient care through personalized therapy, and enhance the treatment of neurological disorders in patients.

Strategic Growth Opportunities for Neurological Biomarker Market

Strategic growth opportunities in neurological biomarkers will emerge across several applications. These range from technological advancements to a focus on improving diagnostic and therapeutic approaches, offering the potential for further market expansion as well as the management of neurological disorders.

• Alzheimer's Disease: The rise in the prevalence of Alzheimer's disease creates a significant avenue for the expansion of neurological biomarkers. Biomarker research is ongoing, with the identification of novel markers currently underway for early detection of the disease and monitoring its progression. Biomarkers that diagnose and track Alzheimer's will be integral in changing treatment outcomes and managing the disease.
• Parkinson's Disease: Other key growth areas of the neurological biomarkers market include Parkinson's disease. Biomarker studies in Parkinson's are on the rise, with new markers being found for monitoring disease progression and treatment response. This area of opportunity is driven by the pressing need for better diagnostic tools and personalized treatment options for patients with Parkinson's.
• Multiple Sclerosis: Biomarkers for MS are a field of growing interest. Improved neuroimaging and biomarker studies enhance the prospects for early diagnosis and follow-up of MS. The development of biomarkers that adequately reflect disease activity and progression is particularly important to optimize treatment strategies and improve patient outcomes.
• Stroke and Traumatic Brain Injury: Biomarkers for stroke and traumatic brain injury are gaining interest as research focuses on early identification and management. Biomarkers that can quickly identify and assess brain injury represent a tremendous development and growth opportunity. These biomarkers will enable early interventions and help patients recover from the impacts of stroke and TBI.
• Neuroinflammation and Neurodegenerative Diseases: The number of biomarkers for neuroinflammation and neurodegenerative diseases continues to increase. Biomarkers associated with neuroinflammatory processes allow for better understanding and management of conditions such as multiple sclerosis and Alzheimer's disease. There is a large need for improved diagnostic and therapeutic tools in neuroinflammation and neurodegeneration.

These strategic growth opportunities drive the neurological biomarkers market by encouraging innovative diagnostics and therapeutic approaches. The high emphasis on Alzheimer's, Parkinson's, multiple sclerosis, stroke, and neuroinflammation is fostering advancements toward developing better biomarkers associated with personalized treatment options, with a view to improving neurological disorder management.

Neurological Biomarker Market Driver and Challenges

There are a few key drivers and challenges that impact the neurological biomarker market. Technological advancements, economic factors, and regulatory considerations can significantly affect market dynamics. While the drivers support growth and innovation, challenges related to cost, regulation, and technology integration must be overcome to fully realize the potential of neurological biomarkers.

The factors responsible for driving the neurological biomarker market include:

• Technological Advancements: The growth of the neurological biomarker market is primarily influenced by technological advances such as AI and neuroimaging. These technologies have contributed to increased precision and speed in biomarker analyses, leading to accurate diagnoses and effective management of neurological disorders. Continuous innovation in technology enhances the capability and effectiveness of biomarker research, improving patient outcomes.
• Increasing Prevalence of Neurological Disorders: The primary factor contributing to market growth is the rising prevalence of neurological disorders such as Alzheimer's, Parkinson's disease, and multiple sclerosis. As these burdens increase, there will be a greater demand for advanced diagnostic tools and biomarkers that improve early diagnosis and treatment. This trend drives research and development in the field.
• Increasing Research and Development Investment: Growth in the neurological biomarker market is fueled by increased investment in research and development. Government agencies, research institutions, and private organizations are funding the development of new biomarkers and diagnostic tools, enabling quicker innovation and contributing to advancements in neurology.
• Focus on Personalized Medicine: The trend toward personalized medicine is driving the development of biomarkers that can target treatments to individual patients. Advances in genomics and proteomics are making it possible to identify biomarkers unique to a particular patient's genetic profile. These trends continue to result in more effective therapies, better treatment outcomes, and enhanced patient care.
• Increased Demand for Early Diagnosis: New biomarkers are being developed in response to the growing demand for early diagnosis of neurological disorders. Since conditions like Alzheimer's and Parkinson's require timely detection, this focus helps ensure effective treatment and management. The emphasis on early diagnosis has accelerated research into biomarkers that can identify diseases in their early stages.

Challenges in the neurological biomarker market include:

• High Development and Implementation Costs: One of the major challenges in the market is the high development and implementation costs of advanced biomarkers. The costs associated with research and development, regulatory approval, and clinical trials can vary significantly, restricting the accessibility of new biomarkers and thus affecting the market.
• Regulatory and Reimbursement Issues: Navigating regulatory requirements and reimbursement for new biomarkers can be difficult. Long regulatory procedures and diverse reimbursement policies may delay the introduction of new diagnostic tools, reducing availability. Addressing these issues is essential for successful commercialization.
• Integration with Existing Systems: New biomarkers and diagnostics often face difficulties integrating with existing healthcare systems. Compatibility and interoperability with previously established systems are key to successful implementation. These integration issues must be resolved for the full benefits of advanced biomarkers to be realized, significantly improving diagnostic workflows.

The drivers and challenges that influence the neurological biomarker market highlight the complexity of emerging technologies, cost and regulatory issues, and market access. While technological advancements and increased investment spur growth, various challenges related to technology, regulation, and integration impede the full realization of neurological biomarkers and their value addition to patient care.

List of Neurological Biomarker Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies neurological biomarker companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neurological biomarker companies profiled in this report include-

• Abbott
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Merck
• Johnson & Johnson Services
• BANYAN BIOMARKERS
• Myriad Genetics

Neurological Biomarker by Segment

The study includes a forecast for the global neurological biomarker by type, application, end use, and region.

Neurological Biomarker Market by Type [Analysis by Value from 2018 to 2030]:

• Genomic
• Proteomic
• Metabolomic
• Imaging
• Others

Neurological Biomarker Market by Application [Analysis by Value from 2018 to 2030]:

• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Autism Spectrum Disorder
• Others

Neurological Biomarker Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospital & Hospital Laboratories
• Independent Clinical Diagnostic Centers
• Research Organizations
• Others

Neurological Biomarker Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Neurological Biomarker Market

The neurological biomarkers market has been undergoing significant changes in recent times, driven by technological innovations and a growing focus on precision medicine. These developments enhance diagnosis and management capabilities for neurological disorders. Established markets such as the United States, China, Germany, India, and Japan have witnessed key research, diagnostics, and treatments.

• United States: In the US, the latest developments in the neurological biomarker market focus on neuroimaging and genetic analysis. Biomarker identification has become more accurate with the integration of AI and machine learning, offering more precise diagnoses and monitoring of neurological diseases. Additionally, there has been a significant influx of clinical trials related to biomarkers for neurodegenerative diseases such as Alzheimer's and Parkinson's, aimed at validating new biomarkers and therapeutic targets.
• China: In China, growth in the neurological biomarker market is driven by the increasing demand for R&D investment. The country is currently focusing on new biomarkers to enable early-stage diagnosis and personalized treatment of neurological disorders. Various researchers in Chinese institutions and international companies are collaborating to accelerate the development of new diagnostic tools and biomarkers. Furthermore, the penetration of healthcare infrastructure facilitates wider access to advanced diagnostic technologies.
• Germany: Germany is uniquely positioned at the forefront of technological advancements in neurological biomarker research. The country excels in high-resolution neuroimaging, allowing for the quantification and identification of biomarkers for personalized medicine. German institutions lead studies to identify and validate biomarkers for several neurological disorders, such as Alzheimer's disease and multiple sclerosis. These advancements enhance diagnostic precision and permit more targeted treatments.
• India: In India, the neurological biomarker market is creating opportunities for the diagnosis of neurological diseases. The adoption of advanced neuroimaging technologies and biomarker studies is increasing in the country. Improved healthcare infrastructure and availability of diagnostic tools accelerate these initiatives. Collaborative research is also believed to be a factor that aids in the discovery of new biomarkers relevant to the Indian population.
• Japan: Japan has exhibited significant growth in the neurological biomarker market, especially concerning biomarkers for neurodegenerative diseases. Recent developments include the use of advanced neuroimaging and biomarker assays to enhance early diagnosis and disease monitoring. Japanese research institutions have also begun exploring new biomarkers related to cognitive disorders and neuroinflammation to facilitate better and more personalized treatment approaches.

Features of the Global Neurological Biomarker Market

Market Size Estimates: Neurological biomarker market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Neurological biomarker market size by type, application, end use, and region in terms of value ($B).

Regional Analysis: Neurological biomarker market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, end use, and regions for the neurological biomarker market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neurological biomarker market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the neurological biomarker market by type (genomic, proteomic, metabolomic, imaging, and others), application (alzheimer's disease, Parkinson's disease, multiple sclerosis, autism spectrum disorder, and others), end use (hospital & hospital laboratories, independent clinical diagnostic centers, and research organizations and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Neurological Biomarker Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Neurological Biomarker Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Neurological Biomarker Market by Type
  • 3.3.1: Genomic
  • 3.3.2: Proteomic
  • 3.3.3: Metabolomic
  • 3.3.4: Imaging
  • 3.3.5: Others
• 3.4: Global Neurological Biomarker Market by Application
  • 3.4.1: Alzheimer's Disease
  • 3.4.2: Parkinson's Disease
  • 3.4.3: Multiple Sclerosis
  • 3.4.4: Autism Spectrum Disorder
  • 3.4.5: Others
• 3.5: Global Neurological Biomarker Market by End Use
  • 3.5.1: Hospital & Hospital Laboratories
  • 3.5.2: Independent Clinical Diagnostic Centers
  • 3.5.3: Research Organizations and Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Neurological Biomarker Market by Region
• 4.2: North American Neurological Biomarker Market
  • 4.2.1: North American Neurological Biomarker Market by Type: Genomic, Proteomic, Metabolomic, Imaging, and Others
  • 4.2.2: North American Neurological Biomarker Market by End Use: Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations and Others
• 4.3: European Neurological Biomarker Market
  • 4.3.1: European Neurological Biomarker Market by Type: Genomic, Proteomic, Metabolomic, Imaging, and Others
  • 4.3.2: European Neurological Biomarker Market by End Use: Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations and Others
• 4.4: APAC Neurological Biomarker Market
  • 4.4.1: APAC Neurological Biomarker Market by Type: Genomic, Proteomic, Metabolomic, Imaging, and Others
  • 4.4.2: APAC Neurological Biomarker Market by End Use: Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations and Others
• 4.5: ROW Neurological Biomarker Market
  • 4.5.1: ROW Neurological Biomarker Market by Type: Genomic, Proteomic, Metabolomic, Imaging, and Others
  • 4.5.2: ROW Neurological Biomarker Market by End Use: Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Neurological Biomarker Market by Type
  • 6.1.2: Growth Opportunities for the Global Neurological Biomarker Market by Application
  • 6.1.3: Growth Opportunities for the Global Neurological Biomarker Market by End Use
  • 6.1.4: Growth Opportunities for the Global Neurological Biomarker Market by Region
• 6.2: Emerging Trends in the Global Neurological Biomarker Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Neurological Biomarker Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neurological Biomarker Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbott
• 7.2: Thermo Fisher Scientific
• 7.3: Bio-Rad Laboratories
• 7.4: Merck
• 7.5: Johnson & Johnson Services
• 7.6: BANYAN BIOMARKERS
• 7.7: Myriad Genetics